← Leaderboards
Jennifer Maxwell Puck
Human Genome Research
$15,361,332
Attributed
$20,589,680
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,938,155 · 12
By mechanism
U54$20,917,735 · 4
P01$12,908,836 · 2
U19$5,118,203 · 1
R01$4,267,066 · 2
R21$466,815 · 1
R03$154,500 · 1
Top collaborators
- Barbara A. Koenig8 shared
- Pui-Yan Kwok8 shared
- Alexander Marson8 shared
- Steven E Brenner4 shared
- Joseph Church4 shared
- Christopher Craig Dvorak4 shared
- Elie Haddad4 shared
- David L Wiest2 shared
Others in their field
Top investigators on “Severe Combined Immunodeficiency”
- Ronald T Mitsuyasu · University Of California Los Angeles$101,655,133
- Taha E Taha · Johns Hopkins University$26,436,390
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$22,498,112
- Michael Watson · American College Of Medical Genetics$17,498,971
- Sumit K Chanda · Scripps Research Institute, The$14,981,889
- Roger Detels · University Of California Los Angeles$14,647,443
Research focus
Severe Combined ImmunodeficiencyGenesCongenital ImmunodeficiencyCellsNeonatal ScreeningProgramsImmune System DiseasesT-LymphocyteBloodImmunologyDiagnosisMutationImmuneParentsSpottingsBaseGene TherapyAffectDefectScreeningRare DiseasesB-LymphocytesPopulation BasedGenetic Variant
Grant awards (73)
Annual Primary Immune Deficiency Treatment Consortium (PIDTC) Workshop and Education Day$20,000
R13 · FY2025 · AI · contact PI
Inherited T cell defects: Diagnosis, Mechanisms and Treatments$2,181,037
P01 · FY2024 · AI
Human Participants and Sequencing$467,684
P01 · FY2024 · AI · contact PI
Annual Primary Immune Deficiency Treatment Consortium (PIDTC) Workshop and Education Day$20,000
R13 · FY2024 · AI · contact PI
Inherited T cell defects: Diagnosis, Mechanisms and Treatments$2,217,974
P01 · FY2023 · AI
Primary Immune Deficiency Treatment Consortium$1,846,257
U54 · FY2023 · AI · contact PI
PIDTC Administrative Unit$1,688,988
U54 · FY2023 · AI · contact PI
Human Participants and Sequencing$306,044
P01 · FY2023 · AI · contact PI
Inherited T cell defects: Diagnosis, Mechanisms and Treatments$87,059
P01 · FY2023 · AI
Annual Primary Immune Deficiency Treatment Consortium (PIDTC) Workshop and Education Day$20,000
R13 · FY2023 · AI · contact PI
Inherited T cell defects: Diagnosis, Mechanisms and Treatments$2,217,974
P01 · FY2022 · AI
PIDTC Administrative Unit$2,086,129
U54 · FY2022 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,846,257
U54 · FY2022 · AI · contact PI
Human Participants and Sequencing$306,187
P01 · FY2022 · AI · contact PI
Inherited T cell defects: Diagnosis, Mechanisms and Treatments$105,480
P01 · FY2022 · AI
Inherited T cell defects: Diagnosis, Mechanisms and Treatments$12,783
P01 · FY2022 · AI
Inherited T cell defects: Diagnosis, Mechanisms and Treatments$2,217,974
P01 · FY2021 · AI
Primary Immune Deficiency Treatment Consortium$1,846,474
U54 · FY2021 · AI · contact PI
PIDTC Administrative Unit$1,842,349
U54 · FY2021 · AI · contact PI
Human Participants and Sequencing$306,390
P01 · FY2021 · AI · contact PI
Inherited T cell defects: Diagnosis, Mechanisms and Treatments$2,217,974
P01 · FY2020 · AI
Primary Immune Deficiency Treatment Consortium$1,869,799
U54 · FY2020 · AI · contact PI
PIDTC Administrative Unit$1,667,101
U54 · FY2020 · AI · contact PI
Human Participants and Sequencing$264,276
P01 · FY2020 · AI · contact PI
Annual Primary Immune Deficiency Treatment Consortium (PIDTC) Workshop and Education Day$17,000
R13 · FY2020 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,604,571
U54 · FY2019 · AI · contact PI
PIDTC Administrative Unit$1,485,717
U54 · FY2019 · AI · contact PI
Primary Immune Deficiency Treatment Consortium Annual Scientific Meeting$9,000
R13 · FY2019 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,533,468
U54 · FY2018 · AI · contact PI
Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening$150,000
U19 · FY2018 · HD · contact PI
Primary Immune Deficiency Treatment Consortium Annual Scientific Meeting$19,000
R13 · FY2018 · AI · contact PI
Primary Immune Deficiency Treatment Consortium$1,543,394
U54 · FY2017 · AI · contact PI
Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening$1,267,951
U19 · FY2017 · HD · contact PI
Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening$78,949
U19 · FY2017 · HD · contact PI
Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening$30,034
U19 · FY2017 · HD · contact PI
Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening$1,175,629
U19 · FY2016 · HD · contact PI
Newborn Screening for T-Cell Disorders: Spectrum and Outcomes$819,228
R01 · FY2016 · AI · contact PI
Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening$1,157,812
U19 · FY2015 · HD · contact PI
Newborn Screening for T-Cell Disorders: Spectrum and Outcomes$520,208
R01 · FY2015 · AI · contact PI
Functional Analysis of Candidate Genes in Primary T Cell Immunodeficiencies$256,220
R21 · FY2015 · AI
Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening$103,574
U19 · FY2015 · HD · contact PI
Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening$1,154,254
U19 · FY2014 · HD · contact PI
Newborn Screening for T-Cell Disorders: Spectrum and Outcomes$518,996
R01 · FY2014 · AI · contact PI
Inherited Disorders of Lymphocyte Development$382,388
R01 · FY2014 · AI · contact PI
Functional Analysis of Candidate Genes in Primary T Cell Immunodeficiencies$210,595
R21 · FY2014 · AI
Newborn Screening for T-Cell Disorders: Spectrum and Outcomes$515,776
R01 · FY2013 · AI · contact PI
Inherited Disorders of Lymphocyte Development$359,444
R01 · FY2013 · AI · contact PI
Inherited Disorders of Lymphocyte Development$382,388
R01 · FY2012 · AI · contact PI
Inherited Disorders of Lymphocyte Development$382,388
R01 · FY2011 · AI · contact PI
Pilot ProgramPilot/Demonstration Project Program (PPP)$57,231
U54 · FY2011 · AI · contact PI
Inherited Disorders of Lymphocyte Development$386,250
R01 · FY2010 · AI · contact PI
Newborn Screening for SCID in a High-Risk Population$77,250
R03 · FY2009 · HD · contact PI
Newborn Screening for SCID in a High-Risk Population$77,250
R03 · FY2008 · HD · contact PI
GENETIC ANALYSIS OF HOST DEFENSE DISORDERS$0
Z01 · FY2005 · HG
CLINICAL AND BASIC STUDIES IN SEVERE COMBINED IMMUNODEFI$0
Z01 · FY2005 · HG
GENETIC ANALYSIS OF HOST DEFENSE DISORDERS$0
Z01 · FY2004 · HG
CLINICAL AND BASIC STUDIES IN SEVERE COMBINED IMMUNODEFI$0
Z01 · FY2004 · HG
GENE TRANSFER FOR THERAPY OF IMMUNODEFICIENCY DISEASE$0
Z01 · FY2003 · HG
GENETIC ANALYSIS OF HOST DEFENSE DISORDERS$0
Z01 · FY2003 · HG
MUTATIONS OF PROGRAMMED CELL DEATH GENE FAS$0
Z01 · FY2003 · HG
IL 2 RECEPTOR GAMMA CHAIN MUTATIONS IN SCID$0
Z01 · FY2003 · HG
GENE TRANSFER FOR THERAPY OF IL 2 RECEPTOR GAMMA CHAINDE$0
Z01 · FY2002 · HG
GENETIC ANALYSIS OF HOST DEFENSE DISORDERS$0
Z01 · FY2002 · HG
MUTATIONS OF PROGRAMMED CELL DEATH GENE FAS$0
Z01 · FY2002 · HG
IL 2 RECEPTOR GAMMA CHAIN MUTATIONS IN SEVERE COMBINEDIM$0
Z01 · FY2002 · HG
GENE TRANSFER THERAPY OF IL 2 RECEPTOR G CHAIN SCIDI$0
Z01 · FY2001 · HG
GENETIC ANALYSIS OF HOST DEFENSE DISORDERS$0
Z01 · FY2001 · HG
MUTATIONS OF PROGRAMMED CELL DEATH GENE FAS$0
Z01 · FY2001 · HG
IL 2 RECEPTOR GAMMA CHAIN MUTATIONS IN SCID$0
Z01 · FY2001 · HG
GENE TRANSFER FOR THERAPY OF IL 2 RECEPTOR GAMMA CHAINDEFICIENT X LINKED SCIDI$0
Z01 · FY2000 · HG
GENETIC ANALYSIS OF HOST DEFENSE DISORDERS$0
Z01 · FY2000 · HG
MUTATIONS OF PROGRAMMED CELL DEATH GENE FAS$0
Z01 · FY2000 · HG
IL 2 RECEPTOR GAMMA CHAIN MUTATIONS IN SEVERE COMBINEDIMMUNODEFICIENCY$0
Z01 · FY2000 · HG